The company intends to use the funds to extend its reach beyond the 400 U.S. hospitals currently using the Karius Test®, an infectious disease diagnostic test that utilizes genomic analysis and artificial intelligence to detect over 1,000 pathogens from a single blood sample, to address demand from healthcare providers to expand access to the Karius Test beyond the hospital setting, and support research into the broader health implications of its microbial cell-free DNA technology beyond infectious diseases.

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

975 Island Dr. 101
Redwood City, CA 94065
USA

Phone

(866) 452-7487

Website

www.kariusdx.com

Email Address

[email protected]

Overview

The Karius test harnesses next-generation sequencing to detect fragments of cell-free DNA from bacteria, viruses, fungi and protozoa that may be circulating in a patient's bloodstream.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Mickey Kertesz

Chief Medical Officer

Asim Ahmed

Chief Scientific Officer

Timothy Blauwkamp

Chief Technical Officer

Sivan Bercovici

VP - Finance

Karen To

VP - Human Resources

Stacy Solorio

Browse more venture capital transactions:

Prev: 5/2/2024: Symbe venture capital transaction
Next: 5/2/2024: Renda venture capital transaction

Share this article

News on VC Transactions

We report on all VC transactions involving tech companies. VC investment data records reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary